Hemophilia B (Factor IX Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 149 Published: June 30, 2022 Report Code: GDGMDHC22207IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B – Drugs In Development, 2022, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 8, 7, 2, 12, 5 and 1 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 1, 6 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).

– The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • AlphaMab Co Ltd

    Amarna Therapeutics BV

    ASC Therapeutics Inc

    Belief Biomed Inc

    Biocad

    Catalyst Biosciences Inc

    Centessa Pharmaceuticals Plc

    Chameleon Biosciences Inc

    Chengdu Rongsheng Pharmaceutical Co Ltd

    Chia Tai Tianqing Pharmaceutical Group Co Ltd

    CSL Ltd

    Daiichi Sankyo Co Ltd

    Expression Therapeutics Inc

    Freeline Therapeutics Holdings Plc

    GC Pharma

    GeneLeap Biotech

    GeneVentiv Therapeutics Inc

    Intellia Therapeutics Inc

    LFB SA

    Logicbio Therapeutics Inc

    Novo Nordisk AS

    OPKO Health Inc

    Pfizer Inc

    RegenxBio Inc

    Sanofi

    Sigilon Therapeutics Inc

    SK Plasma Co Ltd

    Staidson BioPharma Inc

    ToolGen Inc

    UBI Pharma Inc

    UniQure NV

    Zhengzhou Gensciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hemophilia B (Factor IX Deficiency) – Overview

Hemophilia B (Factor IX Deficiency) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemophilia B (Factor IX Deficiency) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemophilia B (Factor IX Deficiency) – Companies Involved in Therapeutics Development

Hemophilia B (Factor IX Deficiency) – Drug Profiles

Hemophilia B (Factor IX Deficiency) – Dormant Projects

Hemophilia B (Factor IX Deficiency) – Discontinued Products

Hemophilia B (Factor IX Deficiency) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hemophilia B (Factor IX Deficiency), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by AlphaMab Co Ltd, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Amarna Therapeutics BV, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by ASC Therapeutics Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Belief Biomed Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Biocad, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Catalyst Biosciences Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Centessa Pharmaceuticals Plc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Chameleon Biosciences Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by CSL Ltd, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Daiichi Sankyo Co Ltd, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Expression Therapeutics Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Freeline Therapeutics Holdings Plc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by GC Pharma, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by GeneLeap Biotech, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by GeneVentiv Therapeutics Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Intellia Therapeutics Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by LFB SA, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Logicbio Therapeutics Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Novo Nordisk AS, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by OPKO Health Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Pfizer Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by RegenxBio Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Sanofi, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Sigilon Therapeutics Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by SK Plasma Co Ltd, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Staidson BioPharma Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by ToolGen Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by UBI Pharma Inc, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by UniQure NV, 2022

Hemophilia B (Factor IX Deficiency) – Pipeline by Zhengzhou Gensciences Inc, 2022

Hemophilia B (Factor IX Deficiency) – Dormant Projects, 2022

Hemophilia B (Factor IX Deficiency) – Dormant Projects, 2022 (Contd..1)

Hemophilia B (Factor IX Deficiency) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Hemophilia B (Factor IX Deficiency), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.